"IF we show 30% RRR or better, watch out.  Financing be damned."

Even below 30% RRR for the primary MACE outcome in the total BETonMACE population (combined statin group) would be impressive. No therapy on top of standard if care has proven in clinical trials as a pre-specified endpoint 3-point MACE reduction for secondary prevention in diabetics with recent ACS event. Based on the post-hoc analysis of ASSURE, I'm still expecting the rosuvastatin sub-group to outperform the atorvastatin sub-group. So whatever the %RRR for the total population (combined statin group), I just hope it ends up being statistically significant. Then, there won't be any question about the success of the trial or the validity of the pre-specified analyses of the primary outcome. I wouldn't be surprised if the %RRR in the rosuvastatin sub-group was double that observed in the atorvastatin sub-group. For example, 40% RRR and 20%RRR for the rosuvastatin and atorvastatin sub-groups, respectively.

 BearDownAZ